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Abstract
Analysis of a Selected Set of Antimicrobial Peptides
The rapid emergence of resistance to classical antibiotics has increased the interest in
novel antimicrobial compounds. Antimicrobial peptides (AMPs) represent an attractive alter-
native to classical antibiotics and a number of different studies have reported antimicrobial
activity data of various AMPs, but there is only limited comparative data available. The
mode of action for many AMPs is largely unknown even though several models have sug-
gested that the lipopolysaccharides (LPS) play a crucial role in the attraction and attach-
ment of the AMP to the bacterial membrane in Gram-negative bacteria. We compared the
potency of Cap18, Cap11, Cap11-1-18m2, Cecropin P1, Cecropin B, Bac2A, Bac2A-NH2,
Sub5-NH2, Indolicidin, Melittin, Myxinidin, Myxinidin-NH2, Pyrrhocoricin, Apidaecin and
Metalnikowin I towards Staphylococcus aureus, Enterococcus faecalis, Pseudomonas aer-
uginosa, Escherichia coli, Aeromonas salmonicida, Listeria monocytogenes, Campylobac-
ter jejuni, Flavobacterium psychrophilum, Salmonella typhimurium and Yersinia ruckeri by
minimal inhibitory concentration (MIC) determinations. Additional characteristics such as
cytotoxicity, thermo and protease stability were measured and compared among the differ-
ent peptides. Further, the antimicrobial activity of a selection of cationic AMPs was investi-
gated in various E. coli LPS mutants.
Cap18 Shows a High Broad Spectrum Antimicrobial Activity
Of all the tested AMPs, Cap18 showed the most efficient antimicrobial activity, in particular
against Gram-negative bacteria. In addition, Cap18 is highly thermostable and showed no
cytotoxic effect in a hemolytic assay, measured at the concentration used. However, Cap18
is, as most of the tested AMPs, sensitive to proteolytic digestion in vitro. Thus, Cap18 is an
excellent candidate for further development into practical use; however, modifications that
should reduce the protease sensitivity would be needed. In addition, our findings from
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analyzing LPS mutant strains suggest that the core oligosaccharide of the LPS molecule is
not essential for the antimicrobial activity of cationic AMPs, but in fact has a protective role
against AMPs.
Introduction
The extensive use of classical antibiotics not only in human medicine, but also in animal farm-
ing for treatment and growth promotion has resulted in the development and spread of antibi-
otic resistance in bacteria. There is now an increasing awareness of the problems for human
health caused by antibiotic resistant bacteria among food producing animals, especially since
many of the same classes of antibiotics are used in both reservoirs [1]. This has emphasized the
need for new solutions to battle infections in farmed animals which are not based on antibiotics
that are considered critically important for human health [2].
Antimicrobial peptides (AMPs) represent an attractive alternative to classical antibiotics.
AMPs are present in all kingdoms of life and are ancient components of the innate immunity
and represent the first line of defense in an infection [3,4]. Despite their diversity in sequence,
they generally have an overall positive charge (+2 to +9) and have a substantial proportion of
hydrophobic amino acids (=>30%). The length normally varies between 10–50 amino acids.
Based on these properties, AMPs are able to fold into amphiphilic three-dimensional struc-
tures, which are divided into 4 major groups: α-helical peptides (e.g. Cecropin B, Cecropin P1,
Melittin, Cap11, Cap18 and magainins); β-sheet peptides with 2–4 disulfide bridges (e.g.
human defensins, plectasin or protegrins); extended peptides which are rich in glycin, proline,
tryptophan, and/or histidine (e.g. Indolicidin, Apidaecin); loop peptides with one disulfide
bridge (e.g. bactenecin). The majority of the so far characterized AMPs belong to the group of
the α-helical peptides and the β-sheet peptides [3][5][6]. AMPs isolated from prokaryotes are
called bacteriocins. One of the best characterized bacteriocins is Nisin, which is originally iso-
lated from Lactococcus lactis. Nisin is active against various major Gram-positive food-borne
pathogens, including Listeria and Clostridium. It is used as food additive and preservative since
1969 in processed cheese, pasteurized milk and milk products and cooked sausages [7].
Classically, the mechanisms of AMP action are thought of as an interaction with the bacterial
cell membrane. Most often, the interaction of an AMP with the membrane will lead to destabili-
zation of the membrane by formation of transient channels, micellarization, and dissolution of
the membrane or translocation across the membrane which results in increased membrane per-
meability. As a result of increased permeability, nutrients and electrolytes will flow out which
lead to killing of the bacteria. However, killing might also happen in a more specific or targeted
manner by recognition of cell surface proteins as a first step followed by insertion in the mem-
brane. Finally, the mode of action might also be targeting metabolic processes in the bacteria
including cell wall synthesis, nucleic acid or protein synthesis, which are vital to the organism [8].
Several studies have reported activity of different peptides useful for food preservation and
safety purposes [7][9][10][11]. However, most of these studies have only focused on a single or
a few peptides and a single or a few bacterial targets. Thus, a major bottleneck in identifying
which new AMPs to choose for further development into practical use is the lack of compre-
hensive overviews comparing the potency of known AMPs from different sources to a broader
range of pathogens. In addition, cytotoxicity and stability is most often ignored, although being
crucial parameters in developing successful AMP alternatives.
In this study, we focused on finding AMPs to inhibit zoonotic and fish pathogens. Aquacul-
ture is a high density animal production system characterized by a high use of antimicrobial
agents. For this study we have selected a handful of peptides reported to have high antibacterial
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activity against Gram-negative bacteria. In addition we required the peptides to be composed
of ordinary L-amino acids, devoid of posttranslational modifications, and to be shorter than 40
aa. These selection criteria were chosen to allow for subsequent development of recombinant
production procedures for peptides with potential applications in food or feed. We compared
the potency of the selected AMPs towards a broad range of pathogens under standardized and
comparable conditions with respect to antimicrobial activity, hemolytic activity, and stability.
In addition, the mode of action of the most potent AMPs has been addressed in the E. coli
ATCC25922 which was chosen as model organism. The present work will facilitate the evalua-
tion and identification of AMPs for further development.
Materials and Methods
Bacterial Strains and Growth Conditions
The strains used in this study are listed in Table 1. The Yersinia ruckeri strain was kindly pro-
vided by Prof. Kurt Buchmann, University of Copenhagen, Faculty of Health and Medical Sci-
ences, and the Flavobacterium psychrophilum strain was kindly provided by Prof. Inger
Dalsgaard, DTU, Denmark. BW25113 is the Escherichia coli wild-type strain, a derivative of
the F-,λ- E. coli K12 strain BD792 which was used in generating the KEIO collection [12][13].
E. coli ATCC25922 is a clinical isolate, serotype O6 and is often used as control strain in anti-
microbial susceptibility testing. All strains were grown in Mueller-Hinton-II medium, except
L.monocytogenes which was grown in BHI medium and F. psychrophilum which was grown in
TYES medium (Tryptone yeast extract plus salts [14]). Incubation took place aerobically at
37°C, except for Y. ruckeri and A. salmonicida, which were grown aerobically at RT (20°C),
Table 1. Strains used in this study.
Strain Relevant characteristics /genotype Reference(s)
Staphyloccous aureus ATCC29213 control strain for antimicrobial susceptibility testing ATCC strain collection
Enterococcus faecalis ATCC29212 control strain for antimicrobial susceptibility testing ATCC strain collection
Pseudomonas aeruginosa
ATCC27853
control strain for antimicrobial susceptibility testing ATCC strain collection
Escherichia coli ATCC25922 Clinical isolate, Serotype O6, Biotype 1, control strain for antimicrobial susceptibility
testing
ATCC strain collection
Aeromonas salmonicida
ATCC33658
Type strain ATCC strain collection
Salmonella enterica serovar
Typhimurium LT2
sequenced strain
Listeria monocytogenes N22-2 Isolate from ﬁsh processing industry [58]
Campylobacter jejuni NCTC11168 Isolate from human feces NCTC strain collection
Flavobacterium psychrophilum
1947
Prof. Inger Dalsgaard, DTU,
Denmark
Yersinia ruckeri 392/2003 [59]
Escherichia coli BW25113 F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), λ-, rph-1, Δ(rhaD-rhaB)568, hsdR514, wild-
type strain used in the KEIO collection
[12][13]
Escherichia coli JW3596 BW25113 rfaC::kan [13]
Escherichia coli JW3024 BW25113 rfaE::kan [13]
Escherichia coli JW3595 BW25113 rfaF::kan [13]
Escherichia coli JW3606 BW25113 rfaG::kan [13]
AD120 Escherichia coli ATCC25922 ΔrfaC This study
AD121 Escherichia coli ATCC25922 ΔrfaE This study
AD122 Escherichia coli ATCC25922 ΔrfaF This study
AD123 Escherichia coli ATCC25922 ΔrfaF This study
doi:10.1371/journal.pone.0144611.t001
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C. jejuni NCTC11168 which was grown under microaerophilic conditions at 42°C and F. psy-
chrophilum 1947 which was grown under aerobic conditions at 15°C. All plates were incubated
for 18–20 hours, except the F. psychrophilum plates, which were incubated for 72 hours.
Antimicrobial peptides
The peptides used in this study are listed in Table 2. Cecropin P1 and Cecropin B were pur-
chased from Sigma-Aldrich. Cecropin P1 with a purity of95% and Cecropin B with a purity
of97% and were dissolved in water. Bac2A-NH2 with a purity of95% and Sub5-NH2 with
a purity95% were purchased from Anaspec (distributed by BioNordika Denmark A/S). The
peptide sequences were confirmed with MS data. Bac2A-NH2 was dissolved in 100% DMSO,
whereas Sub5-NH2 was dissolved in water. Cap18 (89.5% purity, 58% net peptide content),
Cap11 (94.7% purity, 63% net peptide content), Cap11-1-18m2 (87.9% purity, 57% net peptide
content), Bac2A (93.2% purity), Myxinidin (97% purity) and Myxindin-NH2 (97.3% purity,
66% net peptide content) were all synthesized at Genscript. Bac2A, Cap18, Cap11-1-18m2,
Myxinidin and Myxinidin-NH2 were dissolved in water and Cap11 was dissolved in 100%
DMSO. Melittin (RP10290-1) and Indolicidin (RP11242-0.5) each with a purity of>95% were
purchased from Genscript and dissolved in water. The proline rich peptides, Pyrrhocoricin,
Apidaecin IA and Metalnikowin I, were purchased from Anaspec each with a purity of95%
and dissolved in water. All peptides were dissolved to a stock concentration of 10 mg/ml.
Antimicrobial susceptibility testing (MIC testing)
The minimum inhibitory concentrations (MICs) of the AMPs were measured in 96-well
microtiter plates according to the Clinical and Laboratory Standards Institute (CLSI, formerly
Table 2. Sequence and origin of antimicrobial peptides.
Peptide Sequence Origin Structure Reference
Cap11 GLRKKFRKTRKRIQKLGRKIGKTGRKVWKAWREYGQIPYPCRI mammalian, guinea pig,
neutrophils
α-helical [29]
Cap11-1-18m2 KLRKLFRKLLKLIRKLLR truncated derivative of Cap11 α-helical [21]
Cap18 GLRKRLRKFRNKIKEKLKKIGQKIQGLLPKLAPRTDY mammalian, rabbit, neutrophils α-helical [28][30]
Cecropin P1 SWLSKTAKKLENSAKKRISEGIAIAIQGGPR mammalian, pig, small intestine α-helical [32][33]
[34]
Cecropin B KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKALG-NH2 insects, giant silk moth, pupae α-helical [33][35]
Bac2A RLARIVVIRVAR non-amidated version of
Bac2A-NH2
α-helical/β-sheet
Bac2A-NH2 RLARIVVIRVAR-NH2 linear variant of Bactenecin
from bovine neutrophils
Linearized version of
bactenecin
[36][37]
Sub5-NH2 RRWKIVVIRWRR-NH2 synthetic variant of Bac2A-NH2 Not available [36]
Myxinidin GIHDILKYGKPS ﬁsh, epidermal mucus of
Hagﬁsh
Not available [38]
Myxinidin-
NH2
GIHDILKYGKPS-NH2 amidated form of myxinidin Not available
Pyrrhocoricin VDKGSYLPRPTPPRPIYNRN insects, Pyrrhocoris apterus Not available [20]
Apidaecin IA GNNRPVYIPQPRPPHPRI insects, honey bee Extended, proline
rich
[60]
Metalnikowin
I
VDKPDYRPRPRPPNM insects, palomena prasina Not available [19]
Melittin GIGAVLKVLTTGLPALISWIKRKRQQ-NH2 insects, honey bee α-helical [16]
Indolicidin ILPWKWPWWPWR-NH2 mammalian, bovine neutrophils Extended [17]
doi:10.1371/journal.pone.0144611.t002
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National Committee for Clinical Laboratory Standards [NCCLS]) [15]. Briefly, liquid Mueller-
Hinton-II medium containing increasing concentrations of AMPs is inoculated with a defined
number of cells (approx. 105 CFUs/ml) in 96-well microtiter plates (polypropylene), whereas
each plate also includes a positive growth control and a negative control (sterile control). After
incubation, the MIC is determined by the lowest concentration showing no visible growth. All
plates were incubated for 18–20 hours, except the F. psychrophilum plates which were incu-
bated for 72 hours.
All the MIC measurements were carried out in duplicate. The MIC of the reference antibiot-
ics was determined by the use of Sensititre panels (Trek Diagnostic Systems Ltd, East Grin-
stead, UK).
Cytotoxicity assay
The cytotoxicity for each AMP was determined spectrophotometrically by measuring the hae-
moglobin release from horse erythrocytes. Briefly, fresh defibrinated horse blood was washed
three times with PBS, centrifuged for 15 minutes at 1000g and resuspended at 10% (v/v) in
PBS. Samples of the washed horse erythrocytes (100 μl) were transferred to a 96 well microtiter
plate and mixed with 100 μl AMP solution. PBS was used as a negative control, and 0.2% Tri-
tonX-100 was used as a positive control. The microtiter plates were incubated for 60 minutes at
37°C and then centrifuged for 10 minutes at 1300g. The supernatants were transferred to a flat-
bottom 96 well polystyrene microtiter plate and the haemoglobin release was monitored by
measuring the absorbance at 540 nm. The percentage of hemolysis was calculated as 100
(Asample−APBS)/(ATritonX-100 –APBS), where Asample is the experimental absorbance of the pep-
tide sample, APBS is the control absorbance of untreated erythrocytes, and ATritonX-100 is the
absorbance of 0.2% TritonX-100 lysed cells.
Effect of temperature and proteases on antimicrobial activity
AMPs were heated at 70°C or 90° for 5, 15 or 30 minutes. An untreated control, which was
kept at RT, was used as a control. After incubation at 70°C or 90°C, the minimum inhibitory
concentrations (MICs) of the peptides were measured in 96-well microtiter plates according
the Clinical and Laboratory Standards Institute (CLSI, formerly National Committee for Clini-
cal Laboratory Standards [NCCLS]) [15] (see under Antimicrobial susceptibility testing (MIC
testing). E. coli ATCC25922 was used as a test strain for all the AMPs. The effect of proteases,
including trypsin (trypsin ultra, NEB, P8101) and proteinase K (NEB, P8107S), on antimicro-
bial activity of selected AMPs was investigated by incubation with the respective protease at
37°C for either 30 seconds, 2, 5, 15 or 30 minutes. The protease to AMP ratio used in the assay
was 1:100 (w/w) and the buffers used were trypsin-ultra reaction buffer (NEB, P8101) for tryp-
sin and 100 mM Tris-HCl pH 7.5 for proteinase K digestion. To ensure that the trypsin or pro-
teinase K themselves have no antimicrobial activity, each of the protease was used alone in the
corresponding buffer as a control. After incubation, the samples were cooked for 10 minutes at
90°C to inactivate the protease. Afterwards, the antimicrobial activity was determined by mea-
suring the minimal inhibitory concentration (see Antimicrobial susceptibility testing)). E. coli
ATCC25922 was used as a test strain.
Construction of LPS mutants of E. coli ATCC25922
Construction of knock-out mutants of E. coli ATCC25922 were constructed using the λ-Red
recombinase gene replacement system [12]. Primers for amplification of the npt gene of pKD4
are listed in S1 Table. The correct double-crossover and recombination event was confirmed
Comparative Evaluation of Antimicrobial Peptides
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by primers listed in S1 Table and by sequencing. Finally, the kanamycin cassette was removed
[12].
Results
Antimicrobial activity of selected antimicrobial peptides
Fifteen antimicrobial peptides from different classes and origins (Table 2), including the well-
characterized AMPs Melittin [16] and Indoclidin [17], were selected and tested for antimicro-
bial activity. The antimicrobial activity was determined against 10 different bacterial strains
from 10 different species (Table 1) as the minimum inhibitory concentration (MIC), summa-
rized in Table 3. In addition, standard antibiotics from different classes were included for the
comparison of the antimicrobial activity. No activity against F. psychrophilum could be mea-
sured, whereas a varying pattern of activity was found against the other bacterial species tested.
Cap18 had the highest antimicrobial activity of all tested AMPs, in particular against Gram-
negative pathogens, whereas the other cathelicidin, Cap11, was slightly less active. The antimi-
crobial activity of both cathelicidins was in general higher against Gram-negative compared to
Gram-positive bacteria. In contrast, Cap11-1-18m2, which is a short derivative of Cap11, had
only moderate antimicrobial activity against Gram-negative pathogens, but increased antimi-
crobial activity against Gram-positive bacteria compared to the mother peptide Cap11. Inter-
estingly, Cap11-1-18m2 displayed the same high specific activity against C. jejuni as full length
Cap11. Cecropin P1 and Cecropin B showed specific antimicrobial activity against Gram-nega-
tive bacteria, whereas no activity was detected against any of the Gram-positive bacteria tested.
Cecropin B had moderate antimicrobial activity against all tested Gram-negative pathogens,
while Cecropin P1 had specific activity against Y. ruckeri, A. salmonicida and E. coli only.
Bac2A and its amidated form Bac2A-NH2 are linear C2A/C11A variants of the naturally occur-
ring bovine peptide bactenecin. Bac2A displayed very low antimicrobial activity against the
tested microorganisms except for E. faecalis and L.monocytogenes. Sub5-NH2, a synthetic
derivative of Bac2A-NH2 carrying five mutations, had strongly increased antimicrobial activity
compared to the mother peptide Bac2A-NH2. No difference in the specificity between gram-
negative and gram-positive organisms was observed for the bactenectin-derived peptides. The
well-characterized peptide Melittin has good activity against gram-positive bacteria; in particu-
lar S. aureus, E. faecalis and L.monocytogenes. Indolicidin shows only moderate activity except
for L.monocytogenes. Myxinidin, originally isolated from the epidermal mucus of the hagfish,
and it´s amidated form Myxinidin-NH2 displayed no antimicrobial activity under any of the
tested conditions. Pyrrhocoricin, Apidaecin IA and Metalnikowin I are all belonging to the
family of the glycine-rich peptides [18][19][20]. Only Apidaecin showed specific antimicrobial
activity against S. enterica serovar Typhimurium and E. coli, whereas the other AMPs were
ineffective (MIC 256 μg/ml). The potency of the AMPs was compared to the antimicrobial
activity of well-characterized antibiotics from different classes either targeting the bacterial cell
wall, the protein or nucleic acid synthesis. The MIC values for the reference antibiotics are
summarized in Table 3. The solvent DMSO alone had no antimicrobial activity in the concen-
tration range used in the assay (data not shown).
Hemolytic activity
Not only the antimicrobial activity, but also the ability to differentiate between bacterial and
mammalian cells is an important factor for a successful antimicrobial peptide. The cytotoxicity
of the selected AMPs was therefore determined using a hemolytic assay based on lysis of
washed horse erythrocytes. A minimal peptide concentration of 64 μg/ml, which was above or
in the MIC range for the corresponding AMPs, and a maximum peptide concentration of
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256 μg/ml, limited by the experimental setup, was used. Melittin showed a very high hemolytic
activity at the peptide concentration of 128 μg/ml (110% compared to the 0.1% Trition X-100
control), Cap11-l-18m2 showed a significant hemolytic activity (52% compared to the triton X-
100 control) at the peptide concentration of 64 μg/ml and indolicidin was slightly hemolytic
(12% compared to the 0.1% trition X-100 control at the peptide concentration of 128 mg/ml),
whereas the other tested peptides had no to minimal hemolytic activity indicating that they
might be safe to use in the concentrations tested (Table 4). The solvent DMSO alone had no
hemolytic activity in the concentration range used in the assay (data not shown).
Thermostability and protease stability
To address the question of stability, the thermostability and protease stability against the com-
mercial available proteases trypsin and proteinase K was investigated. Only AMPs with high
antimicrobial activity (MIC 32 μg/ml for at least two bacterial species) were included in the
stability assays. E. coli ATCC25922 was used as test strain for both, the thermostability and
protease stability assays.
The thermostability was measured by the determination of the antimicrobial activity of the
peptides after incubation for 5, 15 and 30 minutes at 70°C or 90°C. All the tested peptides
retained their antimicrobial activity even after incubation at 70°C or 90°C for either 5, 15 or 30
minutes (Table 5). All the tested AMPs are stable at high temperatures.
The remaining antimicrobial activity after incubation with either trypsin or proteinase K for
different incubation times is summarized in Table 6. The antimicrobial activity of Cecropin B,
Cecropin P1and Melittin is completely abolished after a very short incubation of only 30 sec-
onds with proteinase K. Cap18 and Indolicidin show a two-fold decreased antimicrobial activ-
ity after incubation with proteinase K for 2 minutes; respectively 4-fold decreased
antimicrobial activity after incubation for 30 minutes. Sub5 shows a similar pattern with a
2-fold reduced activity after 30 sec, a 4-fold reduction after 2 minutes, an 8-fold reduction after
5 minutes, and a 16-fold reduction after 15 or 30 minutes. Interestingly, Cap11-1-18m2 showed
a 2-fold increased antimicrobial activity after very short incubation of 30 seconds or 2 minutes
Table 4. Hemolytic activities of the antimicrobial peptides against horse erythrocytes.
Peptide Peptide Concentration [μg/ml] Hemolytic Activity[%]*
Cap11 64 4 ± 0
Cap11-1-18m2 64 52 ± 6
Cap18 64 1 ± 0
Melittin 128 110 ± 1
Indolicidin 128 12 ± 0
Cecropin P1 256 0 ± 0
Cecropin B 256 0 ± 0
Bac2A 256 0 ± 0
Bac2A-NH2 256 0 ± 0
Sub5-NH2 256 0 ± 0
Myxinidin 256 0 ± 0
Myxinidin-NH2 256 0 ± 0
Pyrrhocoricin 256 0 ± 0
Apidaecin IA 256 0 ± 0
Metalnikowin I 256 0 ± 0
* The hemolytic activity is measured in duplicates and given as the average ± SD in % relative to full lysis
induced by 0.2% Triton X-100.
doi:10.1371/journal.pone.0144611.t004
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with proteinase K. However, incubation of more than 15 minutes with proteinase K leads to
the complete loss of antimicrobial activity of Cap11-1-18m2.
The incubation of Cap18, Cecropin P1, Cecropin B, Melittin and Indolicidin with trypsin
lead to a complete loss of antimicrobial activity after only 30 seconds of incubation. For Cap11,
the incubation with trypsin resulted in a 2-fold decrease of antimicrobial activity after 30 sec-
onds, a 4-fold decrease after 2 minutes, 8-fold decrease after 5 minutes and a complete loss of
activity after 15, respectively 30 minutes. Sub5 followed a similar pattern; incubation with tryp-
sin reduced the antimicrobial activity by factor 2 after 2 and 5 minutes, by factor 4 after 15 min-
utes incubation and by factor 16 after 30 minutes incubation. A short incubation with trypsin
Table 5. Thermostability of antimicrobial peptides.
Temperature
Incubation Time[min]
Antimicrobial Activity MIC [μg/ml]
Cap18 Cap11 Cap11-1-18m2 Cecropin B Cecropin P1 Melittin Indolicidin Sub5
70°C 0 8 8 32 16 16 16 32 4
5 8 8 32 16 16 16 32 4
15 8 8 32 16 16 16 32 4
30 8 8 32 16 16 16 32 8
90°C 0 8 8 32 16 16 16 32 4
5 8 8 32 16 16 16 32 4
15 8 8 32 16 16 16 32 4
30 8 8 32 16 16 16 32 4
Data are collected as minimal inhibitory concentrations (MICs) according to the Clinical and Laboratory Standards Institute (CLSI) and expressed in μml.
All MIC values are the average of ﬁve independent experiments.
doi:10.1371/journal.pone.0144611.t005
Table 6. Protease stability of antimicrobial peptides.
Protease
Incubation Time[min]
Antimicrobial Activity MIC [μg/ml]
Cap18 Cap11 Cap11-1-18m2 Cecropin B Cecropin P1 Melittin Indolicidin Sub5 Gentamicin
Proteinase K 0 8 16 16 16 16 16 32 4 1
0.5 8 16 8 >64 >64 >64 32 8 1
2 16 16 8 >64 >64 >64 32 16 1
5 16 32 16 >64 >64 >64 64 32 1
15 32 64 >64 >64 >64 >64 64 64 1
30 32 >64 >64 >64 >64 >64 64 64 1
Trypsin 0 8 8 16 16 32 16 32 4 1
0.5 >64 16 8 >64 >64 >64 >64 4 1
2 >64 32 8 >64 >64 >64 >64 8 1
5 >64 64 8 >64 >64 >64 >64 8 1
15 >64 >64 32 >64 >64 >64 >64 16 1
30 >64 >64 >64 >64 >64 >64 >64 64 1
Data are collected as minimal inhibitory concentrations (MICs) after incubation with proteinase K or trypsin according to the Clinical and Laboratory
Standards Institute (CLSI) and expressed in μml. All MIC determinations were carried out in triplicates.
doi:10.1371/journal.pone.0144611.t006
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of up to 5 minutes increased the antimicrobial activity of Cap11-1-18m2 by factor 2. Incubation
times longer than 5 minutes lead to a 2-fold reduction, while 15 minutes of incubation
decreases the activity by factor 2, incubation times longer than 30 minutes are leading to a
complete loss of antimicrobial activity. In contrast to thermostability, the majority of the tested
AMPs were highly sensitive towards the proteases trypsin and proteinase K. The antibiotic gen-
tamicin was used as a control, which retained its full antimicrobial activity after incubation
with trypsin or proteinase K for 30 minutes.
Lipopolysaccharides are not target for the AMPs
Previous studies have shown that various AMPs including Cap18, Cap11, Melittin and Indoli-
cidin have LPS binding properties [21][22][23][24][25]. To investigate the potential role of
LPS involved in the mechanism in more detail, the antimicrobial activity of Cap18, Cap11,
Cap11-1-18m2, Cecropin P1, Cecropin B, Indolicidin, Melittin and Sub5 was investigated in a
series of LPS mutants compared with their parental strains, BW25113, an E. coli K12 strain,
and the reference strain ATCC25922. In this study, the rfaC, rfaE, rfaF and rfaG genes were
selected for mutation (Table 7, Fig 1). These genes are involved in the synthesis and assembly
of the core oligosaccharide, the middle part of the LPS molecule connecting the lipid A and the
O-antigen. Except for Cap11, all the tested AMPs showed higher antimicrobial activity in the
BW25113 LPS mutants compared to the parental strain BW25113 (Table 8). The highest
increase (4-8x) in antimicrobial activity was detected for the AMPMelittin in all the BW25113
mutant strains. Cecropin P1 and Cecropin B is 4-8x more active in the BW25113ΔrfaFmutant,
2-4x more active in the BW25113ΔrfaC and BW25113ΔrfaFmutants, up to 2x fold more active
in the BW25113ΔrfaGmutant compared to the wild-type BW25113. Sub5 showed a 2-4x
increased antimicrobial activity, Cap11-1-18m2 and Indolicidin a 2x increased and Cap18 up
to 2x increased antimicrobial activity in all BW25113 LPS mutants. Similar results were
obtained for the LPS mutants in the E. coli reference strain ATCC25922. The highest increase
in antimicrobial activity was observed for Melittin in the ΔrfaC, ΔrfaE and ΔrfaFmutant strains
in which the antimicrobial activity is 8x higher compared to the ATCC25922 wild-type. A
4-fold increase in antimicrobial activity was measured for Melittin in the ATCC25922ΔrfaG
mutant, for Cap11 and Cecropin P1 in the ΔrfaC, ΔrfaE and ΔrfaFmutant strain, for Cecropin
B in the ΔrfaC and ΔrfaEmutant strains and for Sub5 in all tested ATCC25922 LPS mutants.
Cap18, Cap11-1-18m2 and Indolicidin showed a 2-fold increase in activity in all the tested
ATCC25922 LPS mutants, Cap11, Cecropin P1 and Cecropin B were 2-fold more active in the
Table 7. Function and Phenotype of the LPS genes selected in this study.
Gene
Name
Alternative
Gene Name
(s)
Function in core oligosaccharide
assembly
Character of the LPS core Reference
waaC rfaC LPS heptosyltransferase I (HepI).
Adds the ﬁrst heptose sugar onto
the Kdo2 moiety.
Heptoseless [61],[62]
waaE rfaE, hldE Heptose 7-phosphate kinase/
heptose 1-P adenyltransferase
Heptoseless [63][64]
waaF rfaF LPS heptosyltransferase II (HepII).
Transfers the second heptose
sugar onto the heptosyl-Kdo2
moiety.
Kdo2 with one heptose [61]
waaG rfaG LPS glycosyltransferase I. Add the
ﬁrst glucose to the outer core
oligosaccharide
Intact 3 heptose, but outer
core-less. Reduced
phosphorylation of the inner
core
[65][57]
doi:10.1371/journal.pone.0144611.t007
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ATCC25922ΔrfaG background. Summarizing, LPS plays a central role in protecting against
the antimicrobial activity of the tested AMPs, which all showed higher antimicrobial activity in
LPS defective mutants.
Discussion
The number of antibiotic resistant pathogens is increasing and the capacity of currently avail-
able antimicrobial compounds to control bacterial infections is diminishing. Antimicrobial
peptides are an alternative to classical antibiotics to control and fight bacterial infections. How-
ever, the lack of standardized protocols and comprehensive overviews comparing the antimi-
crobial activity, cytotoxicity and stability of known AMPs from different sources is one of the
major challenges in identifying AMPs for further development into practical use. Very often
direct comparison of the antimicrobial activity of different AMPs from different publications is
not possible due to different assay conditions and different peptide purities. This study, com-
paring AMPs from different origins using the same assay conditions, allows a direct compari-
son of the antimicrobial activity, hemolytic activity, and stability of a selection of AMPs against
a broader range of bacteria. In this study, we demonstrate that Cap18 and Cap11, both mem-
bers of the cathelidicin family, displayed a potent efficacy in particular against Gram-negative
pathogens, including pathogens found in fish and poultry production. Direct comparison of
MIC values obtained in this study with previously published results is not feasible due to differ-
ent assays, different strains, and different growth conditions [26][27][28][29][21][30][31][32]
Fig 1. Schematic lipopolysaccharide structures of LPSmutants used in this study. Schematic LPS structures especially highlighting the core
oligosaccharide portion of LPS are illustrated. Structures of the major glycoforms of the core oligosaccharide are based on the structural analysis of an E. coli
K12 derivative, W3100 [66]. Each sugar or amino sugar of the core oligosaccharide is shown by a green (Hep), violet (Gal), grey (Kdo) or blue (Glc).
Phosphate groups on modified sugars are shown by red circles. Hep: L-glycero-D-manno-heptose, Kdo: 3-deoxy-D-manno-oct-2- ulosonic acid, GlcN: N-
acetylglucosamine, Glc: glucose, Gal: galactose.
doi:10.1371/journal.pone.0144611.g001
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[33][34][35][36][37]. In S2 Table we have, however, compared our results to previously
reported antimicrobial activities of the selected peptides. Our results confirm the anti-Gram-
negative activity of Cap18, Cap11, and Cap11-1-18m2, previously reported against E. coli. Our
data extend the range of Gram-negatives investigated for these peptides. For Myxinidin and
Pyrrhocoricin our data contradicts previously published results [20,38,39]. One possible expla-
nation for the different results of Pyrrhocoricin could be attributed to the fact that Cudic et al.
used the C-terminal amidated form of Pyrrhocoricin and Cocianich et al. used Pyrrhocoricin
directly isolated from Pyrrhocoris apterus. For the other peptides we see a mixture of confirma-
tions and contradictions in situations where the combination of peptide and microorganism
has been investigated previously. Our analysis allow this set of peptides to be compared under
identical conditions against a broad range of microorganisms, and thereby to select the poten-
tially most suited candidate for development into an antibacterial product.
Besides a high antimicrobial activity, low cytotoxicity is a desirable characteristic for AMPs
as potential drug candidates. In general, AMPs are binding to the bacterial surface by electro-
static interactions. However, some types of AMPs are able to interact not only with the bacte-
rial surface, but also with the host cells which leads to cell lysis. Very often, the toxicity of
AMPs against eukaryotic cells is one of the major obstacles for their clinical application. Melit-
tin has a strong hemolytic activity and is a prototype of AMPs which are inducing pores, which
is in agreement with previous findings [40]. Only Melittin, Cap11-1-18m2, Indolicidin, and
Cap11 showed hemolytic activity; Cap11 only showed very low hemolytic activity. Using those
peptides as drug candidates would need further modifications reducing the hemolytic activity
and increasing the specificity for bacterial cells. Several different approaches to improve the
specificity are described in literature. Previous studies, show that changing the net charge and
Table 8. Antimicrobial activity of selected AMPs in different LPS backgrounds.
Strain
Antimicrobial Activity MIC [μg/ml]
Cap18 Cap11 Cap11-1-
18m2
Cecropin
P1
Cecropin
B
Indolicidin Melittin Sub5
BW25113 wild-
type
4–8 8 16 16–32 16–32 32 16–32 4–8
BW25113
ΔrfaC
4 8 8 8 8 16 4 2
BW25113 ΔrfaE 4 8 8 8 8 16 4 2
BW25113 ΔrfaF 4 8 8 4 4 16 4 2
BW25113
ΔrfaG
4 8 8 16 16 16 4 2
ATCC25922
wild-type
4 16 32 32 32 32 16 4
ATCC25922
ΔrfaC
2 4 16 8 8 16 2 1
ATCC25922
ΔrfaE
2 4 16 8 8 16 2 1
ATCC25922
ΔrfaF
2 4 16 8 16 16 2 1
ATCC25922
ΔrfaG
2 8 16 16 16 16 4 1
Data are collected as minimal inhibitory concentrations (MICs) according to the Clinical and Laboratory
Standards Institute (CLSI) and expressed in μml. All MIC determinations were carried out in triplicates.
doi:10.1371/journal.pone.0144611.t008
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reducing the hydrophobicity by introducing hydrophilic amino acids is leading to a decreased
hemolytic activity [41][42][43]. Other studies have demonstrated that the introduction of D-
amino acids can lower the hemolytic activity of α-helical AMPs [44]. Cap18 displayed no
hemolysis in our assay using horse erythrocytes. The absence of cytotoxicity should however
be expanded to other relevant species of erythrocytes before Cap18 can safely be developed
into products for specific applications.
A challenge with cationic AMPs in various therapeutic contexts is its susceptibility to pro-
teolytic degradation. Many bacteria have developed proteases, e.g. elastase in Pseudomonas aer-
uginosa, aureolysin and V8 in Staphylococcus aureus, leading to fast degradation of the AMPs.
Moreover, gastrointestinal digestive enzymes, such as pepsin and trypsin, and proteases in the
serum contribute to the low proteolytic stability of the majority of AMPs. Our data show that
Cecropin P1, Cecropin B, Melittin and Indolicidin are highly sensitive to proteolytic degrada-
tion by trypsin or proteinase K. Cap18, Cap11, Cap11-1-18m2 and Sub5 are more stable
towards proteinase K digestion. However, only Cap11, Cap11-1-18m2 and Sub5 showed partial
stability towards trypsin digestion. In summary, these findings corroborate that especially anti-
microbial peptides which have a cationic character will show fast degradation. Recent research
focused on finding ways to improve proteolytic stability of cationic antimicrobial peptides.
Similar strategies which can be used to reduce cytotoxicity are showing potential to reduce pro-
tease susceptibility. The incorporation of non-natural amino acids such as D-amino acids or
amino acid derivate of arginine, the modification of the terminal regions including acetylation,
amidation and hydrophobic tagging and the use of non-peptidic backbones (peptidomimetics)
have been shown to improve the protease stability of AMPs [45] [46][47][42][48].
AMPs to be used as feed ingredients should preferably be heat stable, as feed processing usu-
ally includes a pelleting process involving temperatures between 50°C and 90°C [49]. In order
to reduce the risk of spreading microbial contaminants with the feed the higher end of the tem-
perature range is recommended [50]. Feed enzymes will either have to be applied after the pel-
leting process or the enzyme need to optimized for thermal stability [51]. In contrast to
enzymes all the tested AMPs are highly thermostable.
The mode of action of AMPs largely depends on the bacterial cell surface and the amino
acid composition of the peptide itself. According to a previously described model for the mode
action, AMPs are initially attracted to the bacterial surface most likely by electrostatic bonding
between the cationic peptide and the bacterial surface. Cationic peptides are likely first
attracted by negatively charged lipopolysaccharide molecules in Gram-negative bacteria [8].
The negatively charged Lipopolysaccharide molecule (LPS) is one of major molecular compo-
nents of the outer membrane in Gram-negative bacteria. LPS consist of three distinct compo-
nents: LipidA acts as hydrophobic anchor in the outer membrane. The core oligosaccharide
(core OS) composed of different sugar molecules connects the lipid A with the O-antigen, a
structurally variable polysaccharide made up of repeating oligomeric units (Fig 1). In addition,
bacterial membranes are primarily composed of negatively charged lipids including phosphati-
dylglycerol, cardiolipin and the zwitter ionic phosphatidylethanolamine. Even though the neg-
atively charged LPS molecules are important for initial attraction of cationic peptides to the
membrane, the outer membrane itself also acts as an effective permeability barrier against vari-
ous harmful agents, including hydrophobic antibiotics [52][8][53][54]. In particular, mutants
in the core oligosaccharide of the LPS have been shown to be more susceptible to hydrophobic
agents. E. coli and S. Typhimurium strains that lack heptose in the LPS show a deep rough phe-
notype which is characterized by a reduction in the outer membrane protein content and
increased sensitivity towards detergents and hydrophobic antibiotics [55][56]. An E. coli F540
rfaGmutant which is defective in the inner core of the LPS molecule, has a destabilized outer
membrane and exhibits a 80% reduction of heptose phosphorylation which leads to an
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increased susceptibility towards SDS and Novobiocin [57]. Our data clearly indicates that LPS
in E. coli not only acts in the attraction and attachment of antimicrobial peptides to the outer
membrane, but also functions as a protection barrier against cationic AMPs, very similar to
antibiotics. The mutants defective in the core LPS showed increased susceptibility to the major-
ity of the tested AMPs. The ΔrfaC and ΔrfaEmutants, which are supposed to contain a core
without heptose in E. coli K12 BW25113 and the clinical isolate ATCC25922, showed increased
susceptibility towards Cap18, Cap11-1-18m2, Cecropin P1, Cecropin B, Indolicidin, Melittin
and Sub5. Similarly, both ΔrfaFmutants, having a core oligosaccharide consisting of only one
heptose, were more susceptible for Cap18, Cap11-1-18m2, Indolicidin, Melitin and Sub5. A
slight difference in susceptibility was measured for Cecropin P1 and Cecropin B in the different
E. coli backgrounds. Cecropin P1 and Cecropin B showed increased antimicrobial activity in
BW25113ΔrfaF background compared to ATCC25922ΔrfaF and both ΔrfaC and ΔrfaE
mutants. More distinct differences in susceptibility were measured in rfaGmutant background,
which has an intact inner part of the core oligosaccharide and is only missing a functional
outer part of the core oligosaccharide. The biggest differences in susceptibility between the two
E. coli strains, the K12 derivative BW25113 and the clinical isolate ATCC25922, were measured
for Cap11 in all tested LPS mutants. The antimicrobial susceptibility of Cap11 in the LPS
mutants was identical to the wild-type BW25113 strain. In contrast, the antimicrobial activity
was increased by factor 4 in the ΔrfaC,ΔrfaE,ΔrfaF and by factor 2 in the ΔrfaGmutants com-
pared to the wild-type ATCC25922. These data suggest that the different degrees of susceptibil-
ity are depending on one hand on the character of the LPS mutation and on the other hand on
the nature of the AMP. Interestingly, LPS mutants lacking heptose completely and as conse-
quence also lacking all the negatively charged phosphate groups, showed a higher susceptibility
to the majority of the tested AMPs. This indicates that LPS is not essential for antimicrobial
activity of cationic peptides, even though in previous models LPS are regarded as needed for
attraction and attachment via electrostatic bonding. In addition, the O-antigen does not seem
to have an obvious function in the mode of action for the tested cationic AMPs since the sus-
ceptibility of all tested AMPs in E. coli K12 BW25113, which is missing the O-antigen, and the
clinical isolate ATCC25922 belonging to the serotype O6 are the same, except for Cap11 and
Cap11-1-18m2 which show only a very minor difference.
In summary, Cap18, isolated from rabbit neutrophils, is of all the tested AMPs the most
active and has the highest antimicrobial activity in particular against Gram-negative foodborne
pathogens. Cap18 also showed very low toxicity to horse erythrocytes and was stable at high
temperatures. All these characteristics indicates that Cap18 has potential for further develop-
ment as e.g. food and feed ingredient against infections caused by Gram-negative foodborne
pathogens. However, Cap18 is sensitive to trypsin and proteinase K in vitro and further
improvement addressing protease stability will be needed. In addition, our results indicate that
the LPS do not play a central role in the mechanism of cationic AMPs in Gram-negative bacte-
ria. Our findings indicate that LPS is not important in the attraction of cationic peptides to the
bacterial surface of Gram-negative bacteria, but in fact acts as a protection barrier. However,
other factors than LPS might also be involved in the mode of action, since various cationic
AMPs show antimicrobial activity against Gram-positive bacteria which are lacking LPS.
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